Lannett Company, Inc. announced that the U.S. Food and Drug Administration has notified the company that they have completed the safety review of the Investigational New Drug application for biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies, and concluded that the company may proceed with the proposed clinical investigation. The company said it anticipates the pivotal clinical trial to commence by March 2022 and be completed by early 2023.